首页> 外国专利> New aminopyrrole derivatives are alpha-2 adrenergic receptor modulators, useful for treating metabolic syndrome e.g. hypertension, high cholesterol, insulin resistance, glucose intolerance, atherosclerosis and coronary heart disease

New aminopyrrole derivatives are alpha-2 adrenergic receptor modulators, useful for treating metabolic syndrome e.g. hypertension, high cholesterol, insulin resistance, glucose intolerance, atherosclerosis and coronary heart disease

机译:新的氨基吡咯衍生物是α-2肾上腺素能受体调节剂,可用于治疗代谢综合征。高血压,高胆固醇,胰岛素抵抗,葡萄糖耐受不良,动脉粥样硬化和冠心病

摘要

Aminopyrrole derivatives (I) are new. Aminopyrrole derivatives of formula (I) and their salts are new. R12 : H, linear or branched 1-8C alkyl, 2-8C alkene, 1-8C acyl or 1-8C alkylsulfonyl; either R1-R5 : H, halo, linear or branched 1-8C alkyl, 2-8C alkene, linear or branched 1-8C alkoxy, 3-6C alkoxy, 5-6C bicycloalkyl, polyether chain, 1-5C perfluoroalkyl, 1-8C acyl, OH, SH, primary-, secondary- or tertiary-amine, CN, CO 2H or CO 2R1a; or R1R2, R2R3, R4R3, R4R5 : 4-6C ring; R1a : linear or branched 1-8C alkyl or 3-6C cycloalkyl; R6-R11 : H, linear or branched 1-8C alkyl, 2-8C alkene, 3-6C cycloalkyl or 1-5C perfluoroalkyl; n : 1 or 2; and R13 : H or CH 3. Provided that (I) excludes: R10, R11 is CH 3or H, and then R1 or R5 is cyclopropyl or H; R8, R9 is CH 3or H, and then R1 or R5 is cyclopropyl or H; R10, R11 is CH 3or H, and then R1 or R5 is Cl or H; and #R10, R11 is CH 3or H, then R1 or R5 is Cl or H and R3 is I. [Image] ACTIVITY : Analgesic; Antianginal; Hypotensive; Metabolic; Antidiabetic; Antiarteriosclerotic; Cardiant; Vasotropic; Nephrotropic; Anorectic. MECHANISM OF ACTION : Alpha-2 adrenergic receptor modulator. The alpha -2 adrenergic receptor modulating activity of (I) was tested using competition assay. The result showed that (3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine exhibited an inhibition constant (Ki) value of greater than 10 - 5mu m.
机译:氨基吡咯衍生物(I)是新的。式(I)的氨基吡咯衍生物及其盐是新的。 R12:H,直链或支链的1-8C烷基,2-8C烯烃,1-8C酰基或1-8C烷基磺酰基; R1-R5:H,卤素,直链或支链的1-8C烷基,2-8C烯烃,直链或支链的1-8C烷氧基,3-6C烷氧基,5-6C双环烷基,聚醚链,1-5C全氟烷基,1- 8C酰基,OH,SH,伯,仲或叔胺,CN,CO 2H或CO 2R1a;或R1R2,R2R3,R4R3,R4R5:4-6C环; R1a:直链或支链的1-8C烷基或3-6C环烷基; R6-R11:H,直链或支链的1-8C烷基,2-8C烯烃,3-6C环烷基或1-5C全氟烷基; n:1或2; R13:H或CH3。(I)不包括:R10,R11为CH 3或H,然后R1或R5为环丙基或H;和R8,R9为CH 3或H,然后R1或R5为环丙基或H; R10,R11为CH 3或H,然后R1或R5为Cl或H;和#R10,R11为CH 3或H,则R1或R5为Cl或H,R3为I。抗心绞痛降压;新陈代谢;抗糖尿病抗动脉硬化;卡迪恩变压性嗜肾厌食的。作用机理:α-2肾上腺素能受体调节剂。使用竞争测定法测试(I)的α-2肾上腺素受体调节活性。结果表明,(3-氯-2-甲基-苯基)-(4-甲基-4,5-二氢-3H-吡咯-2-基)-胺表现出的抑制常数(Ki)值大于10-。 > 5>微米。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号